Vanguard Group’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Vanguard Group’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-442,835	Closed	-$1.69M	–	4152
2019 Q3	$1.69M	Buy	442,835 +380	+0.1%	+$1.37K	﹤0.01%	3505
2019 Q2	$2.94M	Buy	442,455 +218,085	+97%	+$830K	﹤0.01%	3354
2019 Q1	$797K	Buy	224,370 +81,939	+58%	+$445K	﹤0.01%	3685
2018 Q4	$565K	Sell	142,431 -211,722	-60%	-$2.71M	﹤0.01%	3711
2018 Q3	$7M	Buy	354,153 +15,251	+5%	+$386K	﹤0.01%	3105
2018 Q2	$10.8M	Buy	338,902 +174,612	+106%	+$6.29M	﹤0.01%	2865
2018 Q1	$6.08M	Buy	164,290 +59,875	+57%	+$3.94M	﹤0.01%	3062
2017 Q4	$8.25M	Buy	+104,415	New	+$7.73M	﹤0.01%	2906

Other funds holding MLNT

Stifel Financial St. Louis, Missouri $121B AUM 21.47% 1-Year Est. Return

Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Condor Capital Management Martinsville, New Jersey $1.34B AUM 13.51% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Group One Trading Chicago, Illinois $73.3B AUM 63.67% 1-Year Est. Return

Oxford Asset Management Oxford, United Kingdom $203M AUM 34.78% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.8M AUM 57.47% 1-Year Est. Return

Vanguard Group's MLNT Position: Q4 2019 in Review

Vanguard Group sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q4 2019, closing a stake of 442,835 shares — an estimated $1.69M sold.

Vanguard Group first reported a position in MLNT in Q4 2017 and held it in 8 quarters. The position peaked at $10.8M in Q2 2018. 37 funds tracked by Wall St. Rank hold MLNT as of Q4 2019.

Vanguard Group reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Vanguard Group sold 442,835 Melinta Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $1.69M.
Vanguard Group first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 8 quarters.
Vanguard Group's Melinta Therapeutics, Inc. Common Stock position peaked at $10.8M in Q2 2018.
37 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Vanguard Group's 13F filing for Q4 2019, filed 14 Feb 2020.